Compare · AXGN vs ELMD
AXGN vs ELMD
Side-by-side comparison of Axogen Inc. (AXGN) and Electromed Inc. (ELMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and ELMD operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.19B, about 6.6x ELMD ($330.0M).
- Over the past year, AXGN is up 216.2% and ELMD is up 111.4% - AXGN leads by 104.7 points.
- AXGN has hit the wire 2 times in the past 4 weeks while ELMD has been quiet.
- AXGN has more recent analyst coverage (8 ratings vs 3 for ELMD).
- Company
- Axogen Inc.
- Electromed Inc.
- Price
- $41.10+4.08%
- $39.94+3.79%
- Market cap
- $2.19B
- $330.0M
- 1M return
- -7.61%
- -0.20%
- 1Y return
- +216.15%
- +111.43%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2011
- News (4w)
- 2
- 0
- Recent ratings
- 8
- 3
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Electromed Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Latest AXGN
- Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
- Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
- SEC Form 4 filed by Director Burke William P. Mr.
- SEC Form 4 filed by Director Tyndall Joseph A.
- SEC Form 4 filed by Director Levine Alan M
- SEC Form 4 filed by Director Johnson John
- SEC Form 4 filed by Director Thomas Paul
- SEC Form 4 filed by Director Wendell Amy Mcbride
- SEC Form 4 filed by Director Weiler Kathy Johnson
- Axogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest ELMD
- Chief Financial Officer Nagel Bradley M. covered exercise/tax liability with 674 shares, decreasing direct ownership by 3% to 18,964 units (SEC Form 4) (for tax liability)
- CEO and President Cunniff James L. exercised 9,700 shares at a strike of $17.25 and sold $354,095 worth of shares (9,700 units at $36.50) (SEC Form 4)
- Chief Financial Officer Nagel Bradley M. exercised 9,601 shares at a strike of $10.50 and sold $428,936 worth of shares (11,801 units at $36.35), decreasing direct ownership by 10% to 19,638 units (SEC Form 4)
- SEC Form SD filed by Electromed Inc.
- Director Skarvan Kathleen exercised 40,000 shares at a strike of $3.82 and sold $1,419,358 worth of shares (40,000 units at $35.48) (SEC Form 4)
- SEC Form 10-Q filed by Electromed Inc.
- Electromed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter
- Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Electromed Inc.